| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 2870 | 2019 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 407 | 2021 |
| Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double … L Thamlikitkul, V Srimuninnimit, C Akewanlop, S Ithimakin, ... Supportive Care in Cancer 25, 459-464, 2017 | 81 | 2017 |
| Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial S Peters, R Dziadziuszko, A Morabito, E Felip, SM Gadgeel, P Cheema, ... Nature medicine 28 (9), 1831-1839, 2022 | 48 | 2022 |
| Clinical correlates of benefit from radium‐223 therapy in metastatic castration resistant prostate cancer A Alva, L Nordquist, S Daignault, S George, J Ramos, C Albany, ... The Prostate 77 (5), 479-488, 2017 | 45 | 2017 |
| LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from … BC Cho, E Felip, AI Spira, N Girard, JS Lee, SH Lee, YV Ostapenko, ... Annals of Oncology 34, S1306, 2023 | 34 | 2023 |
| Successful treatment of IgG and complement‐mediated autoimmune hemolytic anemia with bortezomib and low‐dose cyclophosphamide P Danchaivijitr, J Yared, AP Rapoport American journal of hematology 86 (3), 331-332, 2011 | 27 | 2011 |
| Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non–small-cell lung cancer: Results from LASER301 BC Cho, MJ Ahn, JH Kang, RA Soo, T Reungwetwattana, JCH Yang, ... Journal of Clinical Oncology 41 (26), 4208-4217, 2023 | 25 | 2023 |
| Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced … S Ithimakin, P Theeratrakul, A Laocharoenkiat, A Nimmannit, ... Supportive Care in Cancer 28, 5335-5342, 2020 | 22 | 2020 |
| Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation J Chantharasamee, N Poungvarin, P Danchaivijitr, S Techawatanawanna BMC cancer 19, 1-9, 2019 | 19 | 2019 |
| 1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m) NSCLC … R Dziadziuszko, S Peters, SM Gadgeel, MS Mathisen, SM Shagan, ... Annals of Oncology 32, S950-S951, 2021 | 17 | 2021 |
| Phase I study of dalteparin in combination with sunitinib in patients with metastatic clear cell renal carcinoma MQ Wentink, HMW Verheul, SK Pal, S George, J Voortman, ... Clinical Genitourinary Cancer 16 (1), e1-e9, 2018 | 11 | 2018 |
| Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East … E Mustafa, B Bivas, D Pongwut, C Lingwu, YF Wong, T Hashem, CS Lim, ... Bmc Cancer 21, 1-10, 2021 | 8 | 2021 |
| KEYNOTE‐033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC S Ren, J Feng, S Ma, HJ Chen, Z Ma, C Huang, L Zhang, J He, C Wang, ... International Journal of Cancer 153 (3), 623-634, 2023 | 6 | 2023 |
| Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand N Ngamphaiboon, A Dechaphunkul, J Setakornnukul, T Dechaphunkul, ... BMC cancer 20, 1-10, 2020 | 6 | 2020 |
| Efficacy of combination docetaxel and nintedanib in advanced non-small cell lung cancer in Thailand: a multicenter study K Korphaisarn, P Danchaivijitr, T Reungwetwattana, B Chewaskulyong, ... Frontiers in Oncology 11, 572740, 2021 | 5 | 2021 |
| Benefits of prophylactic percutaneous gastrostomy in patients with nasopharyngeal cancer receiving concurrent chemoradiotherapy: A multicenter analysis T Dechaphunkul, N Ngamphaiboon, P Danchaivijitr, R Jiratrachu, ... American Journal of Otolaryngology 43 (2), 103356, 2022 | 4 | 2022 |
| An optimal cumulative dose of cisplatin in chemoradiotherapy as a definitive treatment for non-metastatic nasopharyngeal carcinoma: a retrospective multicenter study P Danchaivijitr, N Ngamphaiboon, C Jiarpinitnun, E Sirachainan, ... Annals of Oncology 27, vi344, 2016 | 4 | 2016 |
| Lazertinib versus gefitinib tyrosine kinase inhibitors in treatment-naïve patients with EGFR-mutated advanced NSCLC: analysis of the Asian subpopulation in LASER301 T Reungwetwattana, BC Cho, KH Lee, YK Pang, CH Fong, JH Kang, ... Journal of Thoracic Oncology 18 (10), 1351-1361, 2023 | 3 | 2023 |
| Comparison of 3-weekly cisplatin versus 3-weekly carboplatin in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) receiving concurrent chemoradiotherapy (CCRT … A Dechaphunkul, P Danchaivijitr, R Jiratrachu, T Dechaphunkul, ... Annals of Oncology 29, viii384, 2018 | 3 | 2018 |
